<p>Corbevax, the first indigenously produced protein sub-unit vaccine rolled out for 12-14-year-olds on Wednesday by the government, will be priced at Rs 800 per dose in the market.</p>.<p>It will cost Rs 990 per dose (inclusive of GST and administration charges). Currently, it is only available in government Covid vaccination centres free of cost. </p>.<p>Making the announcement at a press conference on Wednesday, Mahima Datla, managing director, Biological E Limited, said the vaccine doses currently being supplied to the government are priced at Rs 145 per dose.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/over-26-lakh-doses-of-corbevax-covid-vaccine-administered-to-12-14-year-olds-on-first-day-1092037.html" target="_blank">Over 2.6 lakh doses of Corbevax Covid vaccine administered to 12-14 year-olds on first day</a></strong></p>.<p>“Corbevax-induced immune response was indicative of over 90% effectiveness against the ancestral strain of SARS-CoV-2, and more than 80% in the case of the Delta strain based on the level of neutralising antibody titers,” said Vikram Paradkar, executive vice president, Biological E.</p>.<p>Corbevax vaccination generates antibody response that is highly persistent for more than six months post-vaccination, while other vaccines have shown a 70-90% drop in titers in a similar duration, he added.</p>.<p>The vaccine has been given emergency use authorisation (EUA) for children aged 12-18 years and adults from 18-80 years.</p>.<p>To date, 30 crore vaccines have been produced, the company said.</p>.<p>He went on to say that the vaccine has an excellent safety profile and minimal reactogenicity.</p>.<p>“No grade 3 or serious adverse events were seen in more than 3,500 subjects. Consistent cross-neutralisation and some of the highest neutralising antibody titers were reported against variants: Beta, Delta and Omicron,” he said.</p>.<p>On the assertion by Dr Jayaprakash Muliyel, member of National Technical Advisory Group on Immunisation (NTAGI) and epidemiologist that NTAGI never recommended use of Corbevax in 12-14-year-olds as no data was shared with them, the company said, at every level, data was shared with NTAGI.</p>.<p><strong>Watch latest videos by DH here:</strong></p>
<p>Corbevax, the first indigenously produced protein sub-unit vaccine rolled out for 12-14-year-olds on Wednesday by the government, will be priced at Rs 800 per dose in the market.</p>.<p>It will cost Rs 990 per dose (inclusive of GST and administration charges). Currently, it is only available in government Covid vaccination centres free of cost. </p>.<p>Making the announcement at a press conference on Wednesday, Mahima Datla, managing director, Biological E Limited, said the vaccine doses currently being supplied to the government are priced at Rs 145 per dose.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/over-26-lakh-doses-of-corbevax-covid-vaccine-administered-to-12-14-year-olds-on-first-day-1092037.html" target="_blank">Over 2.6 lakh doses of Corbevax Covid vaccine administered to 12-14 year-olds on first day</a></strong></p>.<p>“Corbevax-induced immune response was indicative of over 90% effectiveness against the ancestral strain of SARS-CoV-2, and more than 80% in the case of the Delta strain based on the level of neutralising antibody titers,” said Vikram Paradkar, executive vice president, Biological E.</p>.<p>Corbevax vaccination generates antibody response that is highly persistent for more than six months post-vaccination, while other vaccines have shown a 70-90% drop in titers in a similar duration, he added.</p>.<p>The vaccine has been given emergency use authorisation (EUA) for children aged 12-18 years and adults from 18-80 years.</p>.<p>To date, 30 crore vaccines have been produced, the company said.</p>.<p>He went on to say that the vaccine has an excellent safety profile and minimal reactogenicity.</p>.<p>“No grade 3 or serious adverse events were seen in more than 3,500 subjects. Consistent cross-neutralisation and some of the highest neutralising antibody titers were reported against variants: Beta, Delta and Omicron,” he said.</p>.<p>On the assertion by Dr Jayaprakash Muliyel, member of National Technical Advisory Group on Immunisation (NTAGI) and epidemiologist that NTAGI never recommended use of Corbevax in 12-14-year-olds as no data was shared with them, the company said, at every level, data was shared with NTAGI.</p>.<p><strong>Watch latest videos by DH here:</strong></p>
